The Indian Journal of Chest Diseases and Allied Sciences

Register      Login

VOLUME 64 , ISSUE 3 ( July-September, 2022 ) > List of Articles

CASE REPORT

Castleman Disease: A Rare and Intriguing Malady: A Case Series

RR Chinthareddy, H Prithiviraj, SN Zaidi, SV Srikrishna, Vijay Cholenahalli Lingaraju

Keywords : Castleman disease, Hyaline vascular, Mediastinal mass, Unicentric

Citation Information : Chinthareddy R, Prithiviraj H, Zaidi S, Srikrishna S, Lingaraju VC. Castleman Disease: A Rare and Intriguing Malady: A Case Series. Indian J Chest Dis Allied Sci 2022; 64 (3):220-223.

DOI: 10.5005/jp-journals-11007-0024

License: CC BY-NC 4.0

Published Online: 08-12-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Abstract

Castleman disease (CD), first described by Benjamin Castleman as angiofollicular mediastinal lymph–node hyperplasia, is a rare benign lymphoproliferative disorder with varied modes of presentation. Its common presentation within the mediastinum misleads the clinician and merits special attention since it is essentially a diagnosis of exclusion. We are sharing our experience with three patients, within a relatively short period of 2 years. All three presented with a mediastinal mass, however, each of them came with an entirely different clinical scenario and diagnosis. All three were successfully operated and Castleman disease [hyaline–vascular (HV) type] was diagnosed only after the final histopathology.


HTML PDF Share
  1. Simpson D. Epidemiology of Castleman disease. Hematol Oncol Clin North Am 2018;32(1):1–10. DOI: 10.1016/j.hoc.2017.09.001.
  2. Cronin DMP, Warnke RA. Castleman disease: An update on classification and the spectrum of associated lesions. Adv Anat Pathol 2009;(1694):236–246. DOI: 10.1097/PAP.0b013e3181a9d4d3.
  3. Bonekamp D, Horton KM, Hruban RH, et al. Castleman disease: The great mimic. Radiographics 2011;31(6):1793–1807. DOI: 10.1148/rg.316115502.
  4. Koa B, Borja AJ, Aly M, et al. Emerging role of 18F-FDG PET/CT in Castleman disease: a review. Insights Imaging 2021;12, 35.
  5. Wu D, Lim MS, Jaffe ES. Pathology of Castleman disease. Hematol Oncol Clin North Am 2018;32(1):37–52. DOI: 10.1016/j.hoc.2017.09.004.
  6. Wong RSM. Unicentric Castleman disease. Hematol Oncol Clin North Am 2018;32(1):65–73. DOI: 10.1016/j.hoc.2017.09.006.
  7. Boutboul D, Fadlallah J, Chawki S, et al. Treatment and outcome of unicentric Castleman disease: A retrospective analysis of 71 cases. Br J Haematol 2019;186(2):269–273. DOI: 10.1111/bjh.15921.
  8. Talat N, Belgaumkar AP, Schulte KM, et al. Surgery in Castleman's disease: A systematic review of 404 published cases. Ann Surg 2012; 255(4):677–684. DOI: 10.1097/SLA.0b013e318249dcdc.
  9. van Rhee F, Stone K, Szmania S, et al. Castleman disease in the 21st century: An update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol 2010;8(7):486–498. PMID: 20864917.
  10. Safford SD, Lagoo AS, Mahaffey SA. Preoperative embolization as an adjunct to the operative management of mediastinal Castleman disease. J Pediatr Surg 2003;38(9):E21–E23. DOI: 10.1016/s0022-3468(03)00421-4.
  11. Chronowski GM, Ha CS, Wilder RB, et al. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 2001;92(3):670–676. DOI: 10.1002/1097-0142(20010801)92:3<670::aid-cncr1369>3.0.co;2-q.
  12. Ren N, Ding L, Jia E, et al. Recurrence in unicentric Castleman's disease postoperatively: A case report and literature review. BMC Surg 2018;18(1):1.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.